Dr. Karsh graduated from The Chicago Medical School. He completed his General Surgical training at The University of Colorado Health Sciences Center and completed his Urology residency at Brigham and Women’s Hospital/Harvard Medical School.
Dr. Karsh is a co-founder of The Urology Center of Colorado where he serves as an attending Urologist, Director of Research, and co-Chair Advanced Therapeutics Clinic. He specializes in GU Oncology He is a Certified Principal Investigator with an experience of 260 clinical trials. Dr. Karsh has authored a number of peer-reviewed publications and served on the editorial board for Bladder Cancer. He is an active member of the AUA, SUO, ASCO, as well as SWOG. He served on the bladder cancer subcommittee and on the advisory board for the SUO Clinical Trials Consortium from 2010-2020. He served as the principal investigator for the Heat Biologics (HS410) phase 2 and JNJ-56021927(TITAN) Phase 3 clinical trials within the SUO-CTC. Dr. Karsh is also a member of the Denver Academy of Surgeons.
Research trials: Astellas, Astra Zeneca, Arquer,Bayer, Bristol Meyers Squibb, BioXcel, CUSP Group, Dendreon, Epizyme, Exelexis, Exact Sciences, FKD/Feragene, Genentech/Roche, Genomic Health/Exact Sciences,Hinova, Janssen,,KDx, Myovant, OncocellmDx, Pfizer, Tavanta, QED.
Scientific Advisory Committee: Astellas. Vaxiion, Aurora Oncology
Consultant: Astellas, Abbvie, Astra-Zeneca, Aurora Oncology, Bayer, Bristol Meyers Squibb, Dendreon, Genentech/Roche, Janssen, Myovant. Pfizer,Sanofi, UroGPO, Vaxiion, TEMPUS
Speaker: Astellas, Astra Zeneca, Bayer, Janssen, Merck, Myovant, Pylarify,Pfizer